ClinicalTrials.gg
CompletedNCT06278519CARAMBOLEUpdated Oct 19, 2026

CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE)

An interventional study of Blood, urinary and feces collection and Cardiac MRI in Myocardial Infarction, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Basic science

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 168 studies in Myocardial Infarction with a site in France — 22 open to participants now, 31 under way, 7 of them phase 3. Myocardial Infarction · France.

Enrollment
73rd of 114
170 · median 332
Started
2024
with 8 others
No phase
47 of 168
9 open now
Registered
154th of 168
by date

Among the 168 studies in Myocardial Infarction with a site in France, this one is the 73rd largest by enrollment of the 114 interventional ones that give a count, is one of 9 that started in 2024, is one of 47 with no phase, and was the 154th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

22 of the 168 studies in Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Myocardial Infarction with a site in France, or all of them as a file.
02

Study summary

ST-Segment Elevation Myocardial infarction (STEMI) corresponding to acute occlusion of cornary artery is the most severe ischemic myocardial disease and a leading cause of mortality of heart failure worldwide. Although acute mortality from STEMI has decreased over the last decades, the prognosis remains pejorative and difficult to anticipate. The best management of STEMI patients depends of predictive factors of clinical prognosis and justifies an active research of these factors, in particular the mechanisms leading to deleterious left ventricular remodeling, myocardial inflammation, reperfusion injury including the no-reflow phenomenon which is a major determinant of heart failure. Cohorts of consecutive STEMI patients, with a comprehensive assessment of clinical, biological and imaging parameters are needed to offer the basis for new hypothese for research or interventions and to precisely evaluate the quality of care provided.

The main objective of this study is to identify new markers: clinical, biological and imaging, treatment response and prognosis after STEMI.

Secondary objectives of the CARAMBOLE cohort are to establish a comprehensive clinical databse, completed with biological samples and imaging data, that can be used in the following areas:

  • Descriptive epidemiology of STEMI and myocardial reperfusion
  • Evaluation of the clinical implications of the realization of a cardiac MRI at the acute phase of STEMI (regarding no-reflow, LVEF, intra cardiac thrombi)
  • Treatments observatory: safety, efficacy, indication of treatments provided in real life compared to the treatments recommended, adherence to treatments, costs
  • Quality of life, personal, familial, social and professional consequences of myocardial infarction
  • Research of new diagnostic and prognosis biomarkers
  • Research projects (e.g risk of developping cgnitive disorders in patients with STEMI as compared to the general population)

Participants will undergo:

  • a cardiac MRI at the acute phase of their STEMI (5 +/- 3 days) then at 1 year follow-up
  • biological samples including blood, urinary and feces samples, at the acute phase of their STEMI (from admission and up to 8 days) then at 1 year follow-up
  • questionnaire assessment regarding their quality of life, cognitive status,and socio-economic conditions at the acute phase and 1 year follow-up of their STEMI.
Read the detailed description

Myocardial infarction is one of the leading causes of morbi-mortality, causing 75% of cases of sudden death in adults over 35 years of age and more than half of chronic heart failure. Despite the progress made, based on French data from the CIRCUS study and the FAST-MI registry, all-cause mortality at 1 year remained high at around 8% and the rate of occurrence of composite events (death, heart failure, myocardial infarction, revascularization, stroke) estimated around 25%. ST-segment elevation myocardial infarction (STEMI) is the most severe form of ischemic myocardial disease. The recommended treatment is the quickest possible unblocking of the coronary artery responsible for STEMI, by coronary angioplasty (treatment of choice if time limits are compatible) or, more rarely, thrombolysis. However, this revascularization causes undesirable collateral effects with tissue edema, intra-myocardial hemorrhages, microvascular obstruction and local inflammation which contribute to significantly aggravate myocardial damage. These "reperfusion injuries" increase the risk of Left Ventricular (LV) dysfunction. Thus, immediate mortality decreases but the incidence of heart failure following STEMI increases. Several other parameters associated with a poor prognosis remain to this day incompletely understood and treated: deleterious left ventricular remodeling (LVR), post-infarction inflammation, no-reflow.

Furthermore, performing a systematic MRI at the acute phase of STEMI will allow to assess the real prevalence of intra LV thrombi and to treat them before hospital discharge. Indeed, the prevalence of intraLV thrombi is estimated around 20% but only 16% are diagnosed during the stay in the Cardiology Intensive Care Unit (CICU) (low sensitivity of echocardiography, lack of availability of cardiac MRI) . These patients must be treated with anticoagulants to limit the embolic phenomena of intra LV thrombi, in particular strokes, but most patients therefore do not benefit from this treatment when leaving the hospital since MRI is not performed in the acute phase in most centers due to lack of availability.

The organization of prospective cohorts with well-documented biological and imaging collections, in particular the systematic use of myocardial MRI, and monitoring of events at 1 year, will thus make it possible to better understand the complex pathophysiology of these deleterious phenomena, their clinical consequences, to propose research hypotheses and ultimately, to developp innovative and personalized treatments.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • cardiology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥18 years old, hospitalised in cardiology departments at the C.H.U. of Poitiers
  • Myocardial infarction type 1, 2 or 3 according to the 4th universal definition, with elevation of ST segment ≥0.2 milliVolt in two contiguous derivations of the .
  • Patient able to comply with study procedures
  • Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
  • signed by the patient/relative or trusted person after clear and complete information about the clinical investigation.

Exclusion criteria

Exclusion Criteria:

  • Subject with to MRI : pregnancy, ocular metallic foreign body (accidental or other chips), pace-maker incompatible with MRI, foreign ferromagnetic ocular or cerebral bodies, cochlear implants and in general all electronic medical material immovably implanted and incompatible with MRI; metallic heart valve of 1st generation, vascular clips formerly implanted on cranial aneurysm, severe renal insufficiency
  • Patient suffering from claustrophobia
  • to gadoteric acid, to meglumine or to a drug containing gadolinium
  • patients with insufficient venous access for contrast medium injection.
  • Participation in another interventional study with an drug or device, which, in the judgment of the investigator, could interfere with the present study
  • Patients not benefiting from a Social Security scheme or not benefiting from it through a third party
  • Persons benefitting from enhanced protection, namely minors, pregnant women, persons deprived of their liberty by a judicial or administrative decision, patients staying in a health or social establishment, adults under legal protection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Blood and urinary collection, cardiac MRI

    Blood and urinary collection, cardiac MRI at inclusion during acute phase of STEMI, and one year after inclusion visit.

    Biological: Blood, urinary and feces collection · Device: Cardiac MRI · Other: Quality of life and cognitive status questionnaire

Interventions

  • BiologicalBlood, urinary and feces collection

    Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.

  • DeviceCardiac MRI

    Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up

  • OtherQuality of life and cognitive status questionnaire

    Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up

06

What researchers measure

Primary outcomes

  1. Major Adverse cardiac Events (MACE)

    MACE (death, recurrence of myocardial infarction, ischemic stroke, hospitalization for heart failure, unplanned coronary revascularization) will be assessed through medical records and clinical follow-up

    Time frame: Up to 1 year after STEMI

Secondary outcomes

  1. Infarct size

    Infarct size will be measured on Cardiac MRI

    Time frame: Up to 8 days after STEMI

  2. Infarct size

    Infarct size will be measured on Cardiac MRI

    Time frame: 1 year follow-up after STEMI

  3. No-reflow size

    No-reflow size will be measured on Cardiac MRI

    Time frame: Up to 8 days after STEMI

  4. No-reflow size

    No-reflow size will be measured on Cardiac MRI

    Time frame: 1 year follow-up after STEMI

  5. Cardiac enzymes rate

    Cardiac enzymes rate will be analyzed on blood samples

    Time frame: H0 (admission in Intensive Cardiac Care Unit)

  6. Cardiac enzymes rate

    Cardiac enzymes rate will be analyzed on blood samples

    Time frame: H24 (24 hours after reperfusion)

  7. Cardiac enzymes rate

    Cardiac enzymes rate will be analyzed on blood samples

    Time frame: H48 (48 hours after reperfusion)

  8. Cardiac enzymes rate

    Cardiac enzymes rate will be analyzed on blood samples

    Time frame: 1 year follow-up after STEMI

  9. Inflammatory markers rate

    Inflammatory markers rate will be analyzed on blood samples

    Time frame: H0 (admission in Intensive Cardiac Care Unit)

  10. Inflammatory markers rate

    Inflammatory markers rate will be analyzed on blood samples

    Time frame: H24 (24 hours after reperfusion)

  11. Inflammatory markers rate

    Inflammatory markers rate will be analyzed on blood samples

    Time frame: H48 (48 hours after reperfusion)

  12. Inflammatory markers rate

    Inflammatory markers rate will be analyzed on blood samples

    Time frame: 1 year follow-up after STEMI

  13. Gut microbiota profiling

    Gut microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate gut microbiota richness, diversity and composition.

    Time frame: Up to 8 days after STEMI

  14. Gut microbiota profiling

    Gut microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate gut microbiota richness, diversity and composition.

    Time frame: 1 year follow-up after STEMI

  15. Genitourinary microbiota profiling

    Genitourinary microbiota will be assessed on urine samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate genitourinary microbiota richness, diversity and composition.

    Time frame: Up to 8 days after STEMI

  16. Genitourinary microbiota profiling

    Genitourinary microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate genitourinary microbiota richness, diversity and composition.

    Time frame: 1 year follow-up after STEMI

  17. EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version)

    Patients' quality of life will be evaluated by the EQ-5D-3L questionnaire, which ranges from 5 to 15, with a highest score meaning a worse outcome

    Time frame: Up to 8 days after STEMI

  18. EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version)

    Patients' quality of life will be evaluated by the EQ-5D-3L questionnaire, which ranges from 5 to 15, with a highest score meaning a worse outcome

    Time frame: 1 year follow-up after STEMI

  19. Codex test

    Patients' cognitive status will be evaluated by the Codex test

    Time frame: Up to 8 days after STEMI

  20. Codex test

    Patients' cognitive status will be evaluated by the Codex test

    Time frame: 1 year follow-up after STEMI

07

Study locations

1 site
  • C.H.U. of Poitiers
    Poitiers, 86000, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2026, 28 months.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's 28 months is below that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Aug 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Feb 26, 2024
StartActual
Mar 1, 2024
Primary completionActual
Jul 25, 2026was Aug 2026
CompletionActual
Jul 25, 2026was Aug 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Primary completion
Aug 1, 2026→Jul 25, 2026 (actual)
Oct 19, 2026
Study completion
Aug 1, 2026→Jul 25, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion Aug 1, 2026→Jul 25, 2026 (now actual)
    Study completion Aug 1, 2026→Jul 25, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06278519
Collaborators
Fédération Française de Cardiologie
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Mar 1, 2024
Primary completion
Jul 25, 2026
Completion
Jul 25, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion